以下文章来源于e公司 ，作者证券时报 叶玲珍 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价的 主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 思创医惠所涉案件，在此前的公告中或可见端倪。 2022年10月28日，思创医惠因涉嫌信息披露违法违规，被中国证监会立案调查。2024年1月8日，前述事项已查明，公司及相关当事人收到浙江证监局出具的《行政 处罚决定书》。 8月15日晚间，思创医惠（300078）发布公告，公司于8月14日收到杭州市公安局《调取证据通知书》。据悉，杭州市公安局侦办的公司等涉嫌欺诈发行证券案 需调取有关证据材料。 截至目前，案件处于公安机关侦查阶段，尚未有明确结论。公司表示，后续将积极配合调查取证工作，并根据案件进展履行信息披露义务。 针对前述违法行为，浙江证监局决定对思创医惠责令改正，给予警告，并处以8570万元罚款；同时对时任董事长、总经理章笠中给予警告，并处以750万元罚款，并 采取10年市场禁入措施。 思创医惠此前主要经营商业智能及智慧医疗业 ...

Group 1 - The core issue involves a fraud investigation against the company by the Hangzhou Public Security Bureau regarding the alleged fraudulent issuance of securities [1] - The company has previously been under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, leading to administrative penalties [3] - The company was found to have fabricated significant false information in its public bond issuance documents, resulting in inflated revenue and profits for the years 2019 and 2020 [3][4] Group 2 - The company was penalized with a fine of 85.7 million yuan and its former chairman and general manager received individual fines and a 10-year market ban [5] - The company has faced significant revenue declines and continuous losses due to intense industry competition and business adjustments [5] - The company completed the divestiture of its 100% stake in its subsidiary, Medical Technology Co., Ltd., in August 2025 [5]